

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road
Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary medicine

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Serious eye damage/eye irritation : Category 2A

Respiratory sensitisation : Category 1

Skin sensitisation : Category 1

Specific target organ toxicity - repeated exposure (Oral) : Category 1 (ear, Kidney, inner ear)

GHS label elements

Hazard pictograms :



Signal word : Danger

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 5491617-00015 Date of last issue: 25.02.2025
Date of first issue: 10.03.2020

Hazard statements	: H317 May cause an allergic skin reaction. H319 Causes serious eye irritation. H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. H372 Causes damage to organs (ear, Kidney, inner ear) through prolonged or repeated exposure if swallowed.
Precautionary statements	: Prevention: P233 Keep container tightly closed. P260 Do not breathe mist or vapours. P264+P265 Wash hands thoroughly after handling. Do not touch eyes. P270 Do not eat, drink or smoke when using this product. P271 Use only outdoors or with adequate ventilation. P272 Contaminated work clothing should not be allowed out of the workplace. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P284 Wear respiratory protection. Response: P302 + P352 IF ON SKIN: Wash with plenty of water. P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P319 Get medical help if you feel unwell. P333 + P317 If skin irritation or rash occurs: Get medical help. P337 + P317 If eye irritation persists: Get medical help. P342 + P316 If experiencing respiratory symptoms: Get emergency medical help immediately. P362 + P364 Take off contaminated clothing and wash it before reuse. Storage: P403 Store in a well-ventilated place. Disposal: P501 Dispose of contents/ container to an approved waste disposal plant.

Additional Labelling

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 33.36 %

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 5491617-00015 Date of last issue: 25.02.2025
Date of first issue: 10.03.2020

Components

Chemical name	CAS-No.	Concentration (% w/w)
Dihydrostreptomycin sulphate	5490-27-7	$\geq 50 - < 70$
2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate	6130-64-9	$\geq 30 - < 50$
Procaine hydrochloride	51-05-8	$\geq 1 - < 5$
Chlorphenamine hydrogen maleate	113-92-8	$\geq 1 - < 3$
dexamethasone	50-02-2	$\geq 0.025 - < 0.1$

4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome). May cause an allergic skin reaction. Causes serious eye irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. Causes damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂)
------------------------------	--

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

	Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NOx) Sulphur oxides Chlorine compounds Metal oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 5491617-00015 Date of last issue: 25.02.2025
Date of first issue: 10.03.2020

7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Dihydrostreptomycin sulphate	5490-27-7	TWA	4 mg/m3 (OEB 1)	
Further information: OTO				
Chlorphenamine hydrogen maleate	113-92-8	TWA	10 µg/m3 (OEB 3)	Internal
Further information: Skin				
		Wipe limit	100 µg/100 cm2	Internal
dexamethasone	50-02-2	TWA	10 µg/m3 (OEB 3)	Internal
Further information: Skin				
		Wipe limit	100 µg/100 cm2	Internal

- Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

- | | | |
|--------------------------|---|--|
| Respiratory protection | : | If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. |
| Filter type | : | Particulates type |
| Hand protection | : | |
| Material | : | Chemical-resistant gloves |
| Remarks | : | Consider double gloving. |
| Eye protection | : | Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. |
| Skin and body protection | : | Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Contaminated work clothing should not be allowed out of the workplace.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

9. PHYSICAL AND CHEMICAL PROPERTIES

- | | | |
|-----------------|---|--------------------------------|
| Appearance | : | suspension |
| Colour | : | white |
| Odour | : | No data available |
| Odour Threshold | : | No data available |
| pH | : | 5.0 - 6.0
No data available |

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	1.17 - 1.21 g/cm ³ No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	Not applicable

10. STABILITY AND REACTIVITY

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure :

- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

Dihydrostreptomycin sulphate:

Acute oral toxicity : LD50 (Rat): 9,000 - 25,000 mg/kg
LD50 Oral (Mouse): 30,000 mg/kg

2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Acute oral toxicity : LD50 (Mouse): > 2,000 mg/kg

Procaine hydrochloride:

Acute oral toxicity : LD50 (Rat): 200 mg/kg

Chlorphenamine hydrogen maleate:

Acute inhalation toxicity : LC50 (Rat): 0.61 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 89 mg/kg

dexamethasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 6,500 mg/kg
Acute toxicity (other routes of administration) : LD50 (Rat): 14 mg/kg

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

administration) Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Result : No skin irritation

Chlorphenamine hydrogen maleate:

Species : Rabbit
Result : No skin irritation

dexamethasone:

Species : Rabbit
Result : Mild skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Result : No eye irritation

Chlorphenamine hydrogen maleate:

Species : Rabbit
Result : Severe irritation

dexamethasone:

Species : Rabbit
Result : Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

May cause an allergic skin reaction.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Test Type : Maximisation Test

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 5491617-00015 Date of last issue: 25.02.2025
Date of first issue: 10.03.2020

Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : positive
Remarks : Based on data from similar materials

Assessment : Probability or evidence of skin sensitisation in humans

Assessment : Probability of respiratory sensitisation in humans based on animal testing

Chlorphenamine hydrogen maleate:

Exposure routes : Dermal
Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Dihydrostreptomycin sulphate:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Test system: Human lymphocytes
Result: negative

Procaine hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Chlorphenamine hydrogen maleate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Mouse Lymphoma
Result: negative

Test Type: sister chromatid exchange assay
Test system: Chinese hamster ovary cells
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: rat hepatocytes
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

dexamethasone:

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: in vitro assay Test system: mouse lymphoma cells Result: negative
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Dihydrostreptomycin sulphate:

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 5 mg/kg body weight
Result	: negative

Chlorphenamine hydrogen maleate:

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 30 - 60 mg/kg body weight
Result	: negative

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 20 - 50 mg/kg body weight
Result	: negative

Reproductive toxicity

Not classified based on available information.

Components:

Dihydrostreptomycin sulphate:

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 5 mg/kg body weight Test Type: Embryo-foetal development Species: Guinea pig Application Route: Intramuscular
-------------------------------	---

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

General Toxicity Maternal: LOAEL: 100 - 200 mg/kg body weight
Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: Maternal toxicity observed., Embryotoxic effects and adverse effects on the offspring were detected.

Chlorphenamine hydrogen maleate:

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Oral Fertility: LOAEL: 20 mg/kg body weight Result: No effects on fertility, No effects on foetal development
Effects on foetal development	: Test Type: Embryo-foetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 20 mg/kg body weight Result: Reduced embryonic survival, No malformations were observed. Remarks: The significance of these findings for humans is not certain. Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 15 mg/kg body weight Result: No significant adverse effects were reported

dexamethasone:

Effects on foetal development	: Test Type: Development Species: Mouse Application Route: Subcutaneous Developmental Toxicity: LOAEL: 6 mg/kg body weight Result: Specific developmental abnormalities, Cleft palate Species: Rabbit Application Route: Intramuscular Developmental Toxicity: NOAEL: 0.025 mg/kg body weight Result: Specific developmental abnormalities Species: Rabbit Application Route: Intramuscular Developmental Toxicity: LOAEL: ≥ 0.062 mg/kg body weight Result: Specific developmental abnormalities Species: Rat Application Route: Subcutaneous Developmental Toxicity: LOAEL: ≥ 0.02 mg/kg body weight Result: Skeletal and visceral variations, Fetal growth retardation
-------------------------------	---

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

Reproductive toxicity - Assessment : May damage the unborn child.

STOT - single exposure

Not classified based on available information.

Components:

Chlorphenamine hydrogen maleate:

Assessment : May cause drowsiness or dizziness.

STOT - repeated exposure

Causes damage to organs (ear, Kidney, inner ear) through prolonged or repeated exposure if swallowed.

Components:

Dihydrostreptomycin sulphate:

Assessment : Causes damage to organs through prolonged or repeated exposure.

Chlorphenamine hydrogen maleate:

Target Organs : Cardio-vascular system
Assessment : May cause damage to organs through prolonged or repeated exposure.

dexamethasone:

Exposure routes : Oral
Target Organs : Adrenal gland, Immune system, thymus gland
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Dihydrostreptomycin sulphate:

Species : Guinea pig
LOAEL : 40 mg/kg
Application Route : Oral
Exposure time : 90 d
Target Organs : ear
Symptoms : hearing loss

Species : Cat
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 60 d
Target Organs : ear
Symptoms : ataxia, hearing loss, Reduced body weight

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

Species	:	Cat
LOAEL	:	300 mg/kg
Application Route	:	Oral
Exposure time	:	21 d
Target Organs	:	ear
Symptoms	:	ataxia, hearing loss, Reduced body weight

Chlorphenamine hydrogen maleate:

Species	:	Rat
NOAEL	:	10 mg/kg
Application Route	:	Oral
Exposure time	:	6 Weeks
Remarks	:	No significant adverse effects were reported

Species	:	Monkey
LOAEL	:	15 mg/kg
Application Route	:	Oral
Exposure time	:	105 Weeks
Target Organs	:	Heart

dexamethasone:

Species	:	Rat
NOAEL	:	0.0015 mg/kg
Application Route	:	Oral
Exposure time	:	7 d
Target Organs	:	Liver
Remarks	:	Significant toxicity observed in testing

Species	:	Rat
LOAEL	:	0.003 mg/kg
Application Route	:	Oral
Exposure time	:	90 d
Target Organs	:	Blood, Adrenal gland, thymus gland
Remarks	:	Significant toxicity observed in testing

Species	:	Dog
LOAEL	:	0.125 mg/kg
Application Route	:	Oral
Exposure time	:	6 Weeks
Target Organs	:	Adrenal gland
Remarks	:	Significant toxicity observed in testing

Species	:	Rat
LOAEL	:	0.4 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Immune system
Remarks	:	Significant toxicity observed in testing

Species	:	Dog
LOAEL	:	8 mg/kg

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Immune system
Remarks	: Significant toxicity observed in testing

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Dihydrostreptomycin sulphate:

General Information	: Symptoms: Erythema, hearing loss, Nausea, Rash, Vomiting, Headache, hypotension
---------------------	---

Chlorphenamine hydrogen maleate:

Inhalation	: Symptoms: central nervous system effects Remarks: May cause respiratory tract irritation.
Skin contact	: Remarks: May irritate skin.
Eye contact	: Symptoms: Eye irritation Remarks: May cause irreversible eye damage.
Ingestion	: Symptoms: central nervous system effects Remarks: Based on Human Evidence

dexamethasone:

Ingestion	: Target Organs: Immune system Target Organs: Adrenal gland Target Organs: Bone Symptoms: muscle weakness
-----------	--

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Ecotoxicology Assessment

Acute aquatic toxicity	: Toxic effects cannot be excluded
Chronic aquatic toxicity	: Toxic effects cannot be excluded

Procaine hydrochloride:

Ecotoxicology Assessment

Acute aquatic toxicity	: Toxic effects cannot be excluded
Chronic aquatic toxicity	: Toxic effects cannot be excluded

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

dexamethasone:

Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 56 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 9.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	: EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 NOEC: 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic toxicity)	: NOEC: 0.033 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
M-Factor (Chronic aquatic toxicity)	: 1

Persistence and degradability

Components:

dexamethasone:

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 3.54 d Method: OECD Test Guideline 314
------------------	--

Bioaccumulative potential

Components:

Procaine hydrochloride:

Partition coefficient: n-octanol/water	: log Pow: 1.389
--	------------------

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

dexamethasone:

Partition coefficient: n-octanol/water : log Pow: 1.83

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

Revision Date : 14.04.2025

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their

SAFETY DATA SHEET

according to the Globally Harmonized System



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.02.2025
5.0	14.04.2025	5491617-00015	Date of first issue: 10.03.2020

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN